---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-055241"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:18:32.745694+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q1 net loss $88.6M; cash $666.7M; AXPAXLI NDA on track with SOL-1 data

## Summary
- Net loss $88.6M ($0.40 per share) vs $64.1M ($0.38) in Q1 2025; revenue $10.8M, up 0.8%.
- Cash $666.7M as of March 31, 2026; runway into 2028 excluding full AXPAXLI commercialization costs.
- AXPAXLI NDA for wet AMD on track based on SOL-1 Week 52 data; subject to FDA discussions; 505(b)(2) pathway may shorten review.
- SOL-1 positive: superior visual outcomes (74.1% maintained vision at Week 36 vs 55.8% aflibercept); p=0.0006 primary endpoint.
- SOL-R non-inferiority trial on track for topline 1Q 2027; HELIOS-3 ongoing; Investor Day June 17, 2026.

## SEC filing metadata
- accession: 0001104659-26-055241
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/0001104659-26-055241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-055241
- JSON: https://secwatch.observer/filing/0001104659-26-055241.json
- Plain text: https://secwatch.observer/filing/0001104659-26-055241.txt

## Source-grounded claims
- claim_id: 28fb8e3f0e95d976cc032abf8823ba9525bc00a0
  claim: OCULAR THERAPEUTIX, INC reported financial results for first quarter ended March 31, 2026.
  evidence_excerpt: On May 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/0001104659-26-055241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.